Cover Image
市場調查報告書

Medicago Inc. 的產品平台分析

Medicago Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 259370
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
Medicago Inc. 的產品平台分析 Medicago Inc. - Product Pipeline Review - 2015
出版日期: 2015年09月09日 內容資訊: 英文 40 Pages
簡介

Medicago Inc.是總公司設於加拿大的生物科技企業,利用抽取及煉製設備開發H5N1疫苗,季節性流感疫苗,H1N1疫苗,泛發性流感疫苗等。該公司以植物萃取的類病毒顆粒蛋白質表現為基礎的疫苗及抗體製造技術來製造產品。

本報告提供Medicago Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Medicago Inc. 的基本資料

  • Medicago Inc. 概要
  • 主要資訊
  • 企業資料

Medicago Inc. :R&D概要

  • 主要的治療範圍

Medicago Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Medicago Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Medicago Inc. :藥物簡介

  • influenza H1N1 (quadrivalent) (virus like particle) vaccine
  • influenza H5N1 (virus like particle) vaccine + Glucopyranosyl Lipid A Adjuvant
  • influezna H5N1 (virus like particles) vaccine
  • influenza H7N9 (virus like particles) vaccine
  • Biosimilar for Infectious Diseases
  • influenza (virus like particles) vaccine
  • influenza H7N9 (virus like particle) vaccine + Glucopyranosyl Lipid A Adjuvant
  • rabies (virus like particles) vaccine
  • rotavirus (virus like particles) vaccine
  • VLP Vaccine 1 for Infectious Diseases
  • ebola (virus like particles) vaccine
  • VLP Vaccine 2 for Infectious Diseases

Medicago Inc. :開發平台分析

  • 各給藥途徑
  • 各分子類型

Medicago Inc. :最新的開發平台資訊

Medicago Inc. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07554CDB

Summary

Global Markets Direct's, 'Medicago Inc. - Product Pipeline Review - 2015', provides an overview of the Medicago Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Medicago Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Medicago Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Medicago Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Medicago Inc.'s pipeline products

Reasons to buy

  • Evaluate Medicago Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Medicago Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Medicago Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Medicago Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Medicago Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Medicago Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Medicago Inc. Snapshot
    • Medicago Inc. Overview
    • Key Information
    • Key Facts
  • Medicago Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Medicago Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Medicago Inc. - Pipeline Products Glance
    • Medicago Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Medicago Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Medicago Inc. - Drug Profiles
    • influenza [strain H5N1] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [Strains H1N1, H3N2, influenza B] (quadrivalent) virus like particle vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain H5N1] virus like particles vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [Strain H7N9] virus like particle vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar for Infectious Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain H7N9] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza virus like particle vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rabies virus like particle vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rotavirus virus like particle vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VLP Vaccine 1 for Infectious Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ebola virus like particle vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VLP Vaccine 2 for Infectious Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Medicago Inc. - Pipeline Analysis
    • Medicago Inc. - Pipeline Products by Route of Administration
    • Medicago Inc. - Pipeline Products by Molecule Type
  • Medicago Inc. - Recent Pipeline Updates
  • Medicago Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Medicago Inc., Key Information
  • Medicago Inc., Key Facts
  • Medicago Inc. - Pipeline by Indication, 2015
  • Medicago Inc. - Pipeline by Stage of Development, 2015
  • Medicago Inc. - Monotherapy Products in Pipeline, 2015
  • Medicago Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Medicago Inc. - Phase II, 2015
  • Medicago Inc. - Phase I, 2015
  • Medicago Inc. - Preclinical, 2015
  • Medicago Inc. - Discovery, 2015
  • Medicago Inc. - Pipeline by Route of Administration, 2015
  • Medicago Inc. - Pipeline by Molecule Type, 2015
  • Medicago Inc. - Recent Pipeline Updates, 2015
  • Medicago Inc., Other Locations
  • Medicago Inc., Subsidiaries

List of Figures

  • Medicago Inc. - Pipeline by Top 10 Indication, 2015
  • Medicago Inc. - Pipeline by Stage of Development, 2015
  • Medicago Inc. - Monotherapy Products in Pipeline, 2015
  • Medicago Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Medicago Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Medicago Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top